Trial Profile
A Randomized, Sponsor-Open, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Subcutaneous Administration of RO7062931 With Single Ascending Doses in Healthy Volunteers and Multiple Doses and Modified Regimens in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs RO 7062931 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; First in man
- Sponsors Roche
- 26 May 2021 Results from study Part 1 (Single-dose escalation study in healthy volunteers) and Part 2 (Multiple-dose study in patients with CHB) assessing the safety and tolerability of RO7062931, published in the Hepatology.
- 29 Aug 2020 Results from Study Part 2 of multiple dose RO7062931 treatment regimens in patients with chronic hepatitis B (n=59) presented at The International Liver Congress 2020.
- 21 Nov 2019 Status changed from recruiting to completed.